Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Gene Ther. 2011 Nov 3;19(8):818–827. doi: 10.1038/gt.2011.160

Fig. 6. CTLs primed by pshA20-LMP1/2 exhibit enhanced anti-tumor immunity.

Fig. 6

T cells primed by different DCs were injected intraperitoneally into SCID mice bearing EBV+ lymphoma labeled with FFLuc at day 5 and 12 after intraperitoneal tumor implantation. Tumor growth was measured weekly as maximum p/s/cm2/sr. Lines represent the average light emission ± SD (A). Pictures of 3 representative mice per group at day 7 and day 28 (B). The survival curve for SCID mice bearing EBV+ lymphoma that received CTLs primed by differently transfected or Mock DCs (C).